Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVID-19 Vaccination in Rheumatic Diseases
NCT04839315Phase 1Terminated
- Sponsor
- Mayo Clinic
- Start
- Feb 2021
- Primary completion
- Feb 2022
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mRNA COVID-19 vaccine in coronavirus disease 2019 (COVID-19), sponsored by Mayo Clinic. Primary endpoint: Humoral responses towards mRNA COVID-19 vaccines at 6 months. Started Feb 2021; status: terminated.
02
Drugs
mRNA COVID-19 vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04839315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04839315.